■阐明癌症相关成纤维细胞(CAFs)生物标志物与乳腺癌患者个体化CAFs靶向治疗预后之间的关系。
■PubMed,WebofScience,科克伦,和Embase数据库搜索CAFs相关的研究乳腺癌患者从他们开始到9月,2023年。采用R4.2.2软件进行Meta分析。进行敏感性分析以探索异质性的来源。漏斗图和Egger检验用于评估发表偏倚。
■选择了27项研究,包括6,830名患者。单因素分析显示血小板源性生长因子受体-β(PDGFR-β)高表达(P=0.0055),组织金属蛋白酶抑制剂-2(TIMP-2)(P<0.0001),基质金属蛋白酶(MMP)9(P<0.0001),CAF中MMP11(P<0.0001)和MMP13(P=0.0009)分别与无复发生存率(RFS)/无疾病生存率(DFS)/无转移生存率(MFS)/无事件生存率(EFS)相关。多因素分析显示α-平滑肌肌动蛋白(α-SMA)高表达(P=0.0002),后planin(PDPN)(P=0.0008),CAFs和PDGFR-β(P=0.0470)分别与RFS/DFS/MFS/EFS降低相关。此外,低分化乳腺癌患者CAFs中PDPN和PDGFR-β的表达高于相对较高分化的乳腺癌患者。此外,PDPN与人表皮生长因子受体2(HER-2)的表达呈正相关。
■α-SMA的高表达,PDPN,CAFs中的PDGFR-β导致乳腺癌的临床预后较差,表明它们作为预后生物标志物和潜在治疗靶点的作用。
UNASSIGNED: To elucidate the relationship between cancer-associated fibroblast (CAFs) biomarkers and the prognosis of breast cancer patients for individualized CAFs-targeting treatment.
UNASSIGNED: PubMed, Web of Science, Cochrane, and Embase databases were searched for CAFs-related studies of breast cancer patients from their inception to September, 2023. Meta-analysis was performed using R 4.2.2 software. Sensitivity analyses were performed to explore the sources of heterogeneity. Funnel plot and Egger\'s test were used to assess the publication bias.
UNASSIGNED: Twenty-seven studies including 6,830 patients were selected. Univariate analysis showed that high expression of platelet-derived growth factor receptor-β (PDGFR-β) (P = 0.0055), tissue inhibitor of metalloproteinase-2 (TIMP-2) (P < 0.0001), matrix metalloproteinase (MMP) 9 (P < 0.0001), MMP 11 (P < 0.0001) and MMP 13 (P = 0.0009) in CAFs were correlated with reduced recurrence-free survival (RFS)/disease-free survival (DFS)/metastasis-free survival (MFS)/event-free survival (EFS) respectively. Multivariate analysis showed that high expression of α-smooth muscle actin (α-SMA) (P = 0.0002), podoplanin (PDPN) (P = 0.0008), and PDGFR-β (P = 0.0470) in CAFs was associated with reduced RFS/DFS/MFS/EFS respectively. Furthermore, PDPN and PDGFR-β expression in CAFs of poorly differentiated breast cancer patients were higher than that of patients with relatively better differentiated breast cancer. In addition, there is a positive correlation between the expression of PDPN and human epidermal growth factor receptor-2 (HER-2).
UNASSIGNED: The high expression of α-SMA, PDPN, PDGFR-β in CAFs leads to worse clinical outcomes in breast cancer, indicating their roles as prognostic biomarkers and potential therapeutic targets.